$BAX

BAXTER INTERNATIONAL INC (BAX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K BAXTER INTERNATIONAL INC false 0000010456 0000010456 2026-07-31 2026-07-31 0000010456 bax:CommonStock1.00PerValueMember 2026-07-31 2026-07-31 0000010456 bax:GlobalNotes13Due2029Member 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2054

The FDA announced multiple Class I recalls and alerts involving medical devices and related products. Items include certain ventilators and introducer kits, reprocessed electrophysiology and ultrasound catheters by Medline Industries, heart pump controllers by Abiomed, Boston Scientific ACCOLADE pacemakers, and dialysis catheter kits involving Arrow International and Merit Medical. These actions may affect supply and compliance for healthcare providers and investors.

TipRanks highlights analyst activity on PG, SFM, EDU, STLD and BAX. HSBC cut PG to Hold, trimming its $149 target, citing flat organic sales and weaker momentum. J.P. Morgan upgraded SFM to Buy, $103 target. Macquarie raised EDU to Hold, $56.50. Nick Cash initiated STLD Buy, $300 target. Citi upgraded BAX to Hold, $28 target, citing Q2 sales of $2.96B.

Baxter International shares rose about 19% over the week after the company reported encouraging Q2 results. Baxter posted $2.96B revenue, up 5% year over year, and GAAP net income of $135M. Adjusted EPS was $0.56. Analysts expected $2.8B revenue and $0.37 adjusted EPS. Baxter raised FY guidance to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

Deutsche Bank revised its price target for Baxter International to $27 from $20 and kept a Hold rating, according to the bank. Baxter shares were reported around $26.72 in the article’s market snapshot. The change signals an updated valuation view for investors tracking analyst targets and sentiment.

Baxter International (BAX) reported Q2 FY2026 results on July 30, with worldwide sales up 5% to $2.96 billion and adjusted EPS of $0.56, helped by a $0.11 per-share IEEPA tariff refund. The company raised FY2026 guidance to 3% to 4% reported sales growth and adjusted EPS of $1.95 to $2.15. Analysts’ consensus remains Hold; TD Cowen raised its price target to $24.

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

Citigroup upgraded Baxter International to Neutral from Sell and raised its price target to $28 from $17, according to the brokerage. The change signals a revised outlook for the company’s shares and may affect investor expectations and trading around the stock.

Analyst notes list rating and price-target changes for several public companies. CTBC cut Apple to neutral, trimming its target to $353 from $355. Deutsche Bank raised International Paper to buy, target $50 from $39. Other changes include Baxter target $23, Dexcom target $105, Humana target $420, and Stellantis target €5.50.